Patient Square Capital LP Acquires Shares of 151,833 Abivax SA Sponsored ADR $ABVX

Patient Square Capital LP bought a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the third quarter, HoldingsChannel.com reports. The fund bought 151,833 shares of the company’s stock, valued at approximately $12,891,000. Abivax makes up about 3.4% of Patient Square Capital LP’s holdings, making the stock its 4th largest holding.

Several other hedge funds have also recently made changes to their positions in ABVX. Octagon Capital Advisors LP lifted its holdings in shares of Abivax by 3.0% in the 2nd quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after acquiring an additional 37,000 shares during the last quarter. Millennium Management LLC raised its position in Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after purchasing an additional 56,235 shares during the period. Boothbay Fund Management LLC lifted its stake in shares of Abivax by 52.5% in the 2nd quarter. Boothbay Fund Management LLC now owns 870,438 shares of the company’s stock valued at $6,659,000 after purchasing an additional 299,770 shares during the last quarter. Aberdeen Group plc boosted its holdings in shares of Abivax by 10.8% in the 3rd quarter. Aberdeen Group plc now owns 787,417 shares of the company’s stock worth $66,852,000 after purchasing an additional 76,901 shares during the period. Finally, Saturn V Capital Management LP boosted its holdings in shares of Abivax by 12.6% in the 2nd quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock worth $4,762,000 after purchasing an additional 69,553 shares during the period. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABVX. Truist Financial set a $140.00 price target on Abivax in a report on Monday, November 24th. Morgan Stanley increased their target price on shares of Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Guggenheim reaffirmed a “buy” rating and set a $175.00 price target on shares of Abivax in a research note on Thursday, December 18th. Citigroup reiterated a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Finally, Oppenheimer set a $131.00 price objective on shares of Abivax in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $137.00.

Abivax Trading Up 0.1%

ABVX stock opened at $130.35 on Monday. Abivax SA Sponsored ADR has a 12 month low of $4.77 and a 12 month high of $148.83. The firm’s 50-day moving average is $123.15 and its 200 day moving average is $104.40. The company has a market capitalization of $10.31 billion, a PE ratio of -31.18 and a beta of 0.81. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million for the quarter. On average, research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.